scholarly journals The use of an Alpine climate in the treatment of immune thrombocytopenic purpura (ITP) in children of the Kyrgyz Republic

2020 ◽  
Vol 11 (2) ◽  
pp. 2498-2504
Author(s):  
Mamatov Sagynali Murzaevich ◽  
Esengeldi Kyzy Aizhamal ◽  
Vityala Yethindra ◽  
Tugolbai Tagaev Jumabekovich ◽  
Arstanbekova Mira Arstanbekovna ◽  
...  
Keyword(s):  
Platelet Count ◽  
High Altitude ◽  
Sea Level ◽  
Immune Thrombocytopenia ◽  
Hematological Parameters ◽  
Complete Recovery ◽  
Kyrgyz Republic ◽  
Treatment Results ◽  
Thrombocytopenic Purpura ◽  
Chronic Immune Thrombocytopenia

The objective of the study is to evaluate the effectiveness of the use of alpine (high-altitude) climatotherapy in the chronic form of immune thrombocytopenia in children. The article presents the results of the treatment of immune thrombocytopenia in children during high altitude climatotherapy. For this type of treatment, the alpine climate of the Tuya-Ashu pass (3200 meters above sea level) in the Kyrgyz Republic used. A 40-day stay in the highlands contributes to the relief of hemorrhagic syndrome and a significant increase in platelet count. Evaluation of the treatment results showed that out of 32 children who received alpine (high-altitude) climatotherapy once, 2 achieved complete and 14 had partial remission. In 11 children, the improvement of clinical and hematological parameters was temporary, and the absence of effect recorded in 5 patients. 50% of children with chronic immune thrombocytopenia (ITP) responded positively to a single course of treatment. Repeated courses of treatment led only to an improvement in clinical and haematological parameters. In our study, we have a case of a complete recovery of a child with immune thrombocytopenia (ITP) after 5 treatments in high altitude conditions.

Use of high-altitude climate in therapy of childrenwith idiopathic thrombocytopenic purpura in Kyrgyz Republic

2018 ◽  
Author(s):  
С.М. Маматов ◽  
А.К. Эсенгелди ◽  
А.А. Махмануров
Keyword(s):  
Platelet Count ◽  
High Altitude ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Disease Duration ◽  
Hematological Parameters ◽  
Kyrgyz Republic ◽  
Duration Of Treatment ◽  
Thrombocytopenic Purpura ◽  
Hypoxia Exposure ◽  
The Subject

Введение. Вопрос о дальнейшем совершенствовании базисной терапии идиопатической тромбоцитопенической пурпуры (ИТП) по-прежнему широко обсуждается специалистами и является предметом оживленных дискуссий. Цель исследования: изучить динамику геморрагического синдрома и количества тромбоцитов у детей с ИТП в процессе высокогорной климатотерапии и оценить эффективность воздействия высокогорной гипоксии на течение болезни. Материалы и методы. В исследование включено 24 ребенка с хронической ИТП в возрасте от 5 до 14 лет (средний возраст — 10,25 ± 1,43 года) с длительностью заболевания от 4 до 8 лет. Для лечения детей поднимали на высокогорную базу Туя-Ашу (перевал Туя-Ашу, 3200 м над уровнем моря). Продолжительность лечения в высокогорье составляла 40 дней. Результаты. К концу срока пребывания в горах значительно уменьшались проявления геморрагического синдрома, полностью купировался анемический синдром, количество тромбоцитов достоверно увеличивалось с минимума 22,1 × 109/л до максимума 108,4 × 109/л. Заключение. Из 22 детей, получивших высокогорную климатотерапию, у 2 детей достигнута полная и у 15 — частичная ремиссия. У 4 детей улучшение клинико-гематологических показателей носило временный характер, и отсутствие эффекта зарегистрировано у 1 ребенка. Ремиссия достигнута у 77% больных детей. Introduction. Further improvement of the basic therapy of idiopathic thrombocytopenic purpura (ITP) is still widely discussedby specialists and is the subject of lively discussions. Aim: to study the dynamics of hemorrhagic syndrome and platelet count in children with ITP in the process of high-altitude climatotherapy and assess the eff ectiveness of high-altitude hypoxia exposure on the course of the disease. Materials and methods. The study included 24 children with chronic ITP aged 5 to 14 years (mean age — 10.25 ± 1.43 years) with disease duration from 4 to 8 years. For treatment children were raised to Tuya-Ashu high-altitude base (mountain pass Tuya Ashu, 3200 m above sea level). The duration of treatment in highlands was 40 days. Results. By the end of the treatment, the manifestations of hemorrhagic syndrome decreased signifi cantly, the anemic syndrome completely stopped, the platelet count increased significantly from minimum of 22.1 × 109/L to maximum of 108.4 × 109/L. Conclusion. High-altitude climatotherapy received 22 children, 2 children had complete remission and 15 — part remission. In 4 children the improvement of clinical and hematological parameters was temporal, and the absence of eff ect was registered in 1 child. Remission was achieved in 77% of ill children.

scholarly journals Treatment Results of Children With Immune Thrombocytopenic Purpura in the Setting of High-altitude Climate in Kyrgyzstan

2019 ◽  
Vol 5 (5) ◽  
pp. 105-111
Author(s):  
A. Esengeldi ◽  
G. Maimerova ◽  
S. Mamatov
Keyword(s):  
Drug Therapy ◽  
High Altitude ◽  
Hormone Therapy ◽  
Immune Thrombocytopenic Purpura ◽  
Partial Remission ◽  
Hematological Parameters ◽  
Final Diagnosis ◽  
Treatment Results ◽  
Thrombocytopenic Purpura ◽  
Results Of Treatment

The article presents the results of treatment of 27 children with immune thrombocytopenic purpura in the process of high-altitude climate therapy. All children had approved final diagnosis and no positive hormone therapy (prednisone) effects. As a result of the ineffectiveness of drug therapy, patients were sent to the high-altitude climate therapy. In the process of high-altitude climate therapy, two children achieved complete and 17 children achieved partial remission. Improvement of clinical and hematological parameters was temporary in 6 children, and lack of effect was registered in 2 children. During the year of observation, no treatment was needed in children with complete, partial remission and clinical and hematological improvement.

Quality of Life Improvements Following Eltrombopag Treatment in Children with Chronic Immune Thrombocytopenia: Case Report

2021 ◽  
Vol 104 (4) ◽  
pp. 672-675
Keyword(s):  
Quality Of Life ◽  
Platelet Count ◽  
Receptor Agonist ◽  
Immune Thrombocytopenia ◽  
Case Series ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist ◽  
Low Platelet Count ◽  
Chronic Immune Thrombocytopenia

The present case series described six chronic immune thrombocytopenia patients (cITP), with a median age of 7.7 (7.0 to 13.0) years and low platelet count at 15,500 (7,000 to 20,000)/uL. They were suffering from bleeding symptoms and side effects of treatment. After enrollment, they were treated with thrombopoietin receptor agonist (eltrombopag). Five patients responded positively, showing a median platelet count of 115,000 (39,000 to 433,000)/uL. The median dose of eltrombopag used was 1.3 (0.8 to 2.2) mg/kg/day. The quality of life (QoL) improved for all patients, with their median overall score using a Pediatric QoL questionnaire showing 25.0% improvement. Median scores also showed improvements in each sphere of life functioning as physical (30.8%), emotional (26.4%), social (16.4%), and school (21.4%). The present report demonstrated that a select group of cITP patients, with low platelet count and bleeding symptoms, benefitted from treatment with eltrombopag, as shown by increased platelet counts and improved QoL. Keywords: Chronic ITP, Thrombopoietin receptor agonist, Children

Results of high-altitude climate treatment of immune thrombocytopenia in children in the Kyrgyz Republic (five-year analysis)

2020 ◽  
Author(s):  
А.К. Эсенгелди
Keyword(s):  
High Altitude ◽  
Immune Thrombocytopenia ◽  
Disease Duration ◽  
Objective Response ◽  
Kyrgyz Republic ◽  
Chronic Itp ◽  
Effi Ciency ◽  
The Subject ◽  
Further Development

Введение: Вопрос о дальнейшем совершенствовании базисной терапии иммунной тромбоцитопении (ИТП) по-прежнему широко обсуждается специалистами и является предметом оживленных дискуссий. Цель исследования: оценить эффективность высокогорной климатотерапии при хронической ИТП у детей за 5-летний период наблюдения после ежегодного лечения на высокогорной базе. Материалы и методы: В исследование включено 22 ребенка с хронической ИТП в возрасте от 3 до 14 лет, средний возраст — 6,30 ± 1,02 года, длительность заболевания 2-8 лет. Для лечения детей поднимали на высокогорную базу. Продолжительность лечения в высокогорье составляла 40 дней. Результаты: Из 22 детей, получивших 5 курсов высокогорной климатотерапии, у двоих наблюдали полную ремиссию в виде увеличения тромбоцитов более 100×109/л без кровоточивости. Объективный ответ в виде двукратного увеличения числа тромбоцитов, но менее 100×109/л без кровоточивости установлен у 18 детей, отсутствие эффекта было зарегистрировано у 2 детей. Заключение: Повторные курсы высокогорной климатотерапии способствуют улучшению клинической картины, существенному повышению числа тромбоцитов в периферической крови и достижению ремиссии при ИТП у детей. Background: Further development of basic treatment of immune thrombocytopenia (ITP) is still widely discussed by specialists and is the subject of lively discussions. Objectives: to assess the effi ciency of high-altitude climatotherapy in children with chronic ITP for a 5-year follow-up period after annual treatment at high-altitude base. Patients/Methods: The study included 22 children with chronic ITP from 3 to 14 years, the average age was 6.30 ± 1.02 years, and disease duration was 3-8 years. Children were raised to high-altitude base. Treatment duration was 40 days. Results: 22 children received 5 courses of high-altitude climatotherapy. Complete remission was observed in 2 patients with increasing of platelets more than 100×109/L without bleeding. In 18 children an objective response was found in the form of twofold increasing of platelets number, but less than 100×109/L without bleeding; no effect was recorded in 2 children. Conclusions: Repeated courses of high-altitude climatotherapy improve clinical characteristics, significantly increase the number of platelets in the peripheral blood and contribute to remission in children with ITP.

Megakaryocytic Progenitors (CFU-M) Increase Nonspecifically In Chronic Immune Thrombocytopenia

1981 ◽  
Author(s):  
S A Burstein ◽  
S K Erb ◽  
J W Adamson ◽  
L A Harker
Keyword(s):  
Platelet Count ◽  
Immune Thrombocytopenia ◽  
Foreign Protein ◽  
Rabbit Serum ◽  
Normal Rabbit Serum ◽  
Intravenous Injections ◽  
The Mean ◽  
Macrophage Colony ◽  
Phosphate Buffered Saline ◽  
Chronic Immune Thrombocytopenia

Previous studies from our laboratory have suggested that the numbers of CFU-M do not increase primarily in response to acute thrombocytopenia. To determine the effect and specificity of prolonged thrombocytopenia on CFU-M number, mice were given 4 intravenous injections on alternate days of multiply absorbed rabbit anti-mouse platelet serum (APS), while control animals received a similar regimen of rabbit anti-mouse red cell serum (ARS), normal rabbit serum (NRS), or phosphate-buffered saline (PBS). Two days aftefcthe final injection, the mean platelet count was.0.314 ± 0.129 × 106/ul in animals given APS vs. 1.105 ± 0.048 × 106/ul in animals given other regimens. The numbers of CFU-M, day 7 and day 14 erythroid burst forming cells (BFU-E), and granulocyte-macrophage colony forming cells (CFU-C) were determined in humerus and spleen.The generalized increase in progenitor cells in marrow in response to APS together with increases in CFU-M in spleen following ARS and NRS indicate that these cells may respond nonspecifically to foreign protein. The data suggest that the elevation in CFU-M numbers with chronic immune thrombocytopenia is at least partially independent of the platelet count.

scholarly journals Maternal and fetal outcomes of primary immune thrombocytopenia during pregnancy: A retrospective study

2017 ◽  
Vol 11 (1) ◽  
pp. 12-16 ◽  
Author(s):  
KS Gilmore ◽  
C McLintock
Keyword(s):  
Platelet Count ◽  
Immune Thrombocytopenia ◽  
Post Partum ◽  
Bleeding Complications ◽  
Platelet Response ◽  
Thrombocytopenic Purpura ◽  
Primary Immune Thrombocytopenia ◽  
Secondary Outcomes ◽  
Post Partum Haemorrhage ◽  
Auckland Hospital

Objective We reviewed outcomes of 52 pregnancies in 45 women with immune thrombocytopenic purpura who delivered at Auckland Hospital with an antenatal platelet count of <100 × 109/L. Outcome measures Primary outcomes were maternal platelet count at delivery and treatment response. Secondary outcomes included post-partum haemorrhage (PPH). Results Most women had thrombocytopenia at delivery. Treatment with prednisone was given in 14 (27%) pregnancies with responses considered safe for delivery in 11 pregnancies (79%). Women in eight pregnancies also received intravenous immunoglobulin; in five pregnancies (63%) a platelet response acceptable for delivery was achieved. Seventeen pregnancies (33%) were complicated by a PPH ≥500 mL. Ten pregnancies (19%) were complicated by a PPH ≥1000 mL. PPH was reported in all women with a platelet count <50 × 109/L at delivery. Conclusions There were no antenatal bleeding complications but PPH was common among women with platelet counts <50 × 109/L at the time of birth.

scholarly journals Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia

Blood ◽  
2006 ◽  
Vol 109 (6) ◽  
pp. 2470-2476 ◽  
Author(s):  
Rong Deng ◽  
Joseph P. Balthasar
Keyword(s):  
Monoclonal Antibody ◽  
Immune Thrombocytopenia ◽  
Dependent Manner ◽  
Antiplatelet Antibody ◽  
Thrombocytopenic Purpura ◽  
Platelet Counts ◽  
Antibody Immunotherapy ◽  
New Treatment ◽  
Dose Dependent ◽  
Chronic Immune Thrombocytopenia

Abstract The present work evaluated antibody-coated liposomes as a new treatment strategy for immune thrombocytopenic purpura (ITP) through the use of a mouse model of the disease. Effects of antimethotrexate antibody (AMI)–coated liposomes and intravenous immunoglobulin (IVIG)–coated liposomes (15, 30, 60 μmol lipid/kg) were compared with the effects of IVIG (0.4, 1, 2 g/kg) and anti–red blood cell (anti-RBC) monoclonal antibody immunotherapy (TER119, 5, 15, 25, and 50 μg/mouse) on MWReg30-induced thrombocytopenia. Each treatment was found to attenuate thrombocytopenia in a dose-dependent manner and, consistent with previous work, IVIG was found to increase antiplatelet antibody clearance in a dose-dependent manner. TER119 demonstrated greater effects on thrombocytopenia relative to other therapies (peak platelet counts: 224% ± 34% of initial platelet counts for 50 μg TER119/mouse versus 160% ± 34% for 2 g/kg IVIG, 88% ± 36% for 60 μmol lipid/kg AMI-coated liposomes, and 80% ± 25% for 60 μmol lipid/kg IVIG-coated liposomes). However, the effects of TER119 were associated with severe hemolysis, as TER119 decreased RBC counts by approximately 50%. The present work demonstrated that antibody-coated liposomes attenuated thrombocytopenia in this model at a much lower immunoglobulin dose than that required for IVIG effects and, in contrast with TER119, antibody-coated liposomes increased platelet counts without altering RBC counts.

scholarly journals Chronic Immune Thrombocytopenia and Hashimoto’s Hypothyroidism in an Adolescent: Presentation and Implications

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Judy Ibrahim ◽  
Mohammad Alashqar ◽  
Shamma Al Zaabi ◽  
Omar Trad ◽  
Amar Al Shibli
Keyword(s):  
Platelet Count ◽  
Immune Thrombocytopenia ◽  
Adult Population ◽  
Blood Platelet ◽  
Hashimoto Thyroiditis ◽  
Immune Mediated ◽  
Immunosuppressive Medications ◽  
Population Treatment ◽  
Blood Platelet Count ◽  
Chronic Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is a disorder characterized by immune-mediated destruction of thrombocytes leading to peripheral blood platelet count of <100 × 10^9/L. Primary ITP is a terminology used in the absence of other causes or disorders that may be associated with thrombocytopenia, i.e., isolated thrombocytopenia. The term secondary ITP is used if such diseases coexist. We present here a case of a 14-year-old female diagnosed with immune thrombocytopenia. When her evaluation was not strongly supportive of primary ITP, she was screened and proved to have a concomitant Hashimoto thyroiditis. Contrary to the popular belief about secondary ITP in adult population, treatment of our patient’s hypothyroidism did not improve her platelet’s count, and the patient needed multiple immunosuppressive medications to improve her condition.

scholarly journals Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis

Blood ◽  
2014 ◽  
Vol 124 (22) ◽  
pp. 3295-3307 ◽  
Author(s):  
Katja M. J. Heitink-Pollé ◽  
Joyce Nijsten ◽  
Chantal W. B. Boonacker ◽  
Masja de Haas ◽  
Marrie C. A. Bruin
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Platelet Count ◽  
Immune Thrombocytopenia ◽  
Meta Analysis ◽  
Chronic Itp ◽  
Insidious Onset ◽  
Key Points ◽  
Immunoglobulin Treatment ◽  
Chronic Immune Thrombocytopenia

Key Points Older age, insidious onset, no preceding infection, mild bleeding, and higher platelet count are the strongest risk factors for chronic ITP. Intravenous immunoglobulin treatment seems to protect against development of chronic ITP.

Acute thrombocytopenia: picking a way through a paucity of platelets

2019 ◽  
Vol 80 (9) ◽  
pp. 507-512
Author(s):  
E Nuttall Musson ◽  
O Lomas ◽  
MF Murphy
Keyword(s):  
Platelet Count ◽  
Adult Patient ◽  
General Hospital ◽  
Disseminated Intravascular Coagulation ◽  
Immune Thrombocytopenia ◽  
Underlying Disease ◽  
Hospital Physician ◽  
Case Histories ◽  
Thrombocytopenic Purpura ◽  
In Pregnancy

Thrombocytopenia is defined as a platelet count under 150x109/litre. It may be found as a bystander to other pathology or directly related to an underlying haematological condition. Apart from laboratory artefact, it should be treated seriously as it often reflects serious underlying disease. This review uses short case histories to illustrate how to approach thrombocytopenia during the initial presentation of an adult patient to hospital. This article guides the general hospital physician through the narrow but potentially confusing differential diagnoses related to thrombocytopenia, with particular focus on immune thrombocytopenia, disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Thrombocytopenia in pregnancy deserves special consideration and will not be discussed in this article.

Sign in / Sign up

Export Citation Format

Share Document